J.P. Morgan Sticks to Its Hold Rating for Johnson & Johnson (JNJ)

J.P. Morgan analyst Chris Schott maintained a Hold rating on Johnson & Johnson today and set a price target of $205.00. The company’s shares opened today at $191.48.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Schott covers the Healthcare sector, focusing on stocks such as Pfizer, Eli Lilly & Co, and Johnson & Johnson. According to TipRanks, Schott has an average return of 1.8% and a 51.33% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $207.00 average price target, implying an 8.11% upside from current levels. In a report released today, Bank of America Securities also reiterated a Hold rating on the stock with a $204.00 price target.

JNJ market cap is currently $459.8B and has a P/E ratio of 18.42.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year. Last month, Jennifer L Taubert, the EVP, WWC. Innovative Medicine of JNJ sold 56,471.00 shares for a total of $10,040,543.80.